The parasitic worm lives in the soil and enters the body through the feet. The infection is common in parts of Africa, Asia and South America.
By feeding on victims' blood, the worms cause anemia and, in children, stunted growth and learning problems.
Now, researchers at Washington University School of Medicine in St Louis have decoded the genome of the hookworm, Necator americanus, finding clues to how it infects and survives in humans and to aid in development of new therapies to combat hookworm disease.
"This information will accelerate development of new diagnostic tools and vaccines against the infection," said Mitreva.
Necator americanus causes about 85 per cent of human hookworm infections, which are not usually fatal, researchers said.
However, in pregnant women, the worm can cause severe anemia, leading to maternal deaths and low birth weights that contribute to newborn deaths, they said.
The deworming drug albendazole typically is given as part of mass treatment programs in areas with endemic infection, but its repeated and excessive use is leading to treatment failures and drug resistance in some regions, Mitreva said.
After the eggs hatch, the immature worms, called larvae, molt twice and enter the body through the feet.
The worms travel through the bloodstream to the lungs, where they are coughed up and then swallowed, making their way to the small intestine. It is there that the worms mature and begin feeding on the blood.
Decoding the worm's genome allowed the researchers to discover suites of genes that orchestrate each of these processes and to identify specific targets that may be vulnerable to vaccines or new drug treatments.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
